

**REMARKS**

Claims 1, 2, 4-18, 20-32, 34-42, 44-47, 49-54, and 57-66 are pending. Claims 3, 19, 33, 40, 43, 48, and 55-56 have been canceled, without prejudice. Claims 16-18, 20-32, 34-39, 41-42, 44-47, 49-54, and 62-66 have been withdrawn as being drawn to a non-elected invention. Applicants expressly reserve their right to pursue the withdrawn claims in a separate application.

**RESPONSIVE REMARKS**

The PTO requires the restriction of the claims in the above-identified application into one of an alleged eight groups of claims. In the Office Action mailed September 28, 2010, the claims were divided into six groups, Group I, claims 1, 2, 4-15, and 57-61 drawn to a pharmaceutical composition for the treatment of an inflammatory disease comprising a water-soluble polymer linked to a therapeutic agent, wherein the polymer accumulates at the treatment site; Group II, claims 16-18 and 20-24, drawn to a method of treating an inflammatory disease; Group III, claims 25-28, drawn to a method of administering an aqueous composition to a subject; Group IV, claims 29-32, 34-39, 41, 42, 44-46 and 62, drawn to a composition for imaging and evaluating an inflammatory disease comprising a water-soluble polymer linked to a medical imaging agent; Group V, claims 47, 49-54 and 63, drawn to a composition for imaging and evaluating an inflammatory disease in a subject; and Group VI, claims 64-66, drawn to a composition comprising a water-soluble copolymer linked to a glucocorticoid.

Additionally, the PTO requires a further election if Group I is elected. Specifically, the PTO requires Applicant to elect: (a) a single water-soluble polymer, selected from the respective order recited in claim 4; (b) one or more targeting moieties, selected from the respective order recited in claim 10; (c) a selection of one or more monomers comprised within the water-soluble

polymer, selected from the respective order recited in claims 13 and 14; and (d) one or more therapeutic agents, selected from the respective order recited in claim 15.

In response, Applicants elect Group I claims 1, 2, 4-15, and 57-61 and further elect (a) a HPMA copolymer; (b) peptides; (c) N-(2-hydroxypropyl)methacrylamide; and (d) glucocorticoids. Applicants submit that the election of Group I presented above is being made without prejudice to filing a divisional or continuation application directed to the non-elected subject matter.

Thus, examination of all the subject matter of claims 1, 2, 4-15, and 57-61 is respectfully requested. Favorable consideration of claims 1, 2, 4-15, and 57-61 is earnestly solicited.

**ATTORNEY DOCKET NO. 21101.0130U2**  
**APPLICATION NO. 10/591,258**

A credit card payment submitted via EFS Web in the amount of \$65.00, representing the fee for a small entity under 37 C.F.R. § 1.17(a)(1) is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

BALLARD SPAHR LLP

/Scott D. Marty, Reg. No. 53,277/  
Scott D. Marty  
Registration No. 53,277

BALLARD SPAHR LLP  
Customer Number 23859  
(678) 420-9300  
(678) 420-9301 (fax)

<b>CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8</b>			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Mailing (Print/Type)	Scott D. Marty, Ph.D.		
Signature	/Scott D. Marty, Reg. No. 53,277/	Date	/November 29, 2010/